Behandling av akutt kritisk sykdom
Kostnadsbesparelser
Systematisk og multimodal behandling
Improved outcomes and reduced costs associated with a health-system-wide patient blood management program: a retrospective observational study in four major adult tertiary-care hospitals. (åpner nytt vindu)
Kilde: Transfusion 2017;57(6):1347-58.
Arkiv: PubMed 28150313
DOI: 10.1111/trf.14006
https://www.ncbi.nlm.nih.gov/pubmed/28150313 (åpner nytt vindu)
Implementation of a patient blood management monitoring and feedback program significantly reduces transfusions and costs. (åpner nytt vindu)
Kilde: Transfusion 2015;55(12):2807-15.
Arkiv: PubMed 26264557
DOI: 10.1111/trf.13260
https://www.ncbi.nlm.nih.gov/pubmed/26264557 (åpner nytt vindu)
Non-essential blood tests in the intensive care unit: a prospective observational study. [Tests sanguins non essentiels á l’unité de soins intensifs : une étude observationnelle prospective.] (åpner nytt vindu)
Kilde: Can J Anaesth 2017;64(3):290-5.
Arkiv: PubMed 28000153
DOI: 10.1007/s12630-016-0793-9
https://www.ncbi.nlm.nih.gov/pubmed/28000153 (åpner nytt vindu)
Trauma-induced coagulopathy: impact of the early coagulation support protocol on blood product consumption, mortality and costs. (åpner nytt vindu)
Kilde: Crit Care 2015;19:83.
Arkiv: PubMed 25880548
DOI: 10.1186/s13054-015-0817-9
https://www.ncbi.nlm.nih.gov/pubmed/25880548 (åpner nytt vindu)
Effect of a restrictive transfusion strategy on transfusion-attributable severe acute complications and costs in the US ICUs: a model simulation. (åpner nytt vindu)
Kilde: BMC Health Serv Res 2007;7:138.
Arkiv: PubMed 17764560
DOI: 10.1186/1472-6963-7-138
https://www.ncbi.nlm.nih.gov/pubmed/17764560 (åpner nytt vindu)
Behandling av anemi
Cost-effectiveness of recombinant human erythropoietin for reducing red blood cells transfusions in critically ill patients. (åpner nytt vindu)
Kilde: Value Health 2005;8(2):105-16.
Arkiv: PubMed 15804319
DOI: 10.1111/j.1524-4733.2005.04006.x
https://www.ncbi.nlm.nih.gov/pubmed/15804319 (åpner nytt vindu)
Hemostatika
Recombinant activated factor VII use in critically ill infants with active hemorrhage. (åpner nytt vindu)
Kilde: J Pediatr Surg 2008;43(12):2235-8.
Arkiv: PubMed 19040942
DOI: 10.1016/j.jpedsurg.2008.08.053
https://www.ncbi.nlm.nih.gov/pubmed/19040942 (åpner nytt vindu)
The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients. (åpner nytt vindu)
Kilde: Health Technol Assess 2013;17(10):1-79.
Arkiv: PubMed 23477634
DOI: 10.3310/hta17100
https://www.ncbi.nlm.nih.gov/pubmed/23477634 (åpner nytt vindu)